{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:24:30Z","timestamp":1792455870638,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40257-023-00792-6","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T15:01:56Z","timestamp":1684335716000},"page":"595-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials"],"prefix":"10.1007","volume":"24","author":[{"given":"Linda","family":"Stein Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra R.","family":"Natalie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Meskimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elmaraghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Montmayeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"792_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2222.2007.02679.x","volume":"37","author":"J Harrop","year":"2007","unstructured":"Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. 2007;37:526\u201335.","journal-title":"Clin Exp Allergy"},{"key":"792_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","volume":"36","author":"R Sacotte","year":"2018","unstructured":"Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36:595\u2013605.","journal-title":"Clin Dermatol"},{"key":"792_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1346-8138.2006.00187.x","volume":"33","author":"H Saeki","year":"2006","unstructured":"Saeki H, Tsunemi Y, Fujita H, et al. Prevalence of atopic dermatitis determined by clinical examination in Japanese adults. J Dermatol. 2006;33:817\u20139.","journal-title":"J Dermatol"},{"key":"792_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360.","journal-title":"Lancet"},{"issue":"3","key":"792_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"792_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/DER.0000000000000034","volume":"25","author":"JI Silverberg","year":"2014","unstructured":"Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107\u201314.","journal-title":"Dermatitis"},{"issue":"4","key":"792_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11882-008-0049-z","volume":"8","author":"G Yosipovitch","year":"2008","unstructured":"Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep. 2008;8(4):306\u201311.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"792_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"792_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","volume":"119","author":"PP Vakharia","year":"2017","unstructured":"Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-52.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"792_CR10","doi-asserted-by":"crossref","unstructured":"Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327\u201349","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"792_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5414\/ALX02259E","volume":"27","author":"D St\u00f6lzl","year":"2021","unstructured":"St\u00f6lzl D, Weidinger S, Drerup K. A new era has begun: treatment of atopic dermatitis with biologics. Allergol Select. 2021;27:265\u201373.","journal-title":"Allergol Select."},{"key":"792_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1203475420982553","volume":"25","author":"K Ratnarajah","year":"2021","unstructured":"Ratnarajah K, Le M, Muntyanu A, et al. Inhibition of IL-13: a new pathway for atopic dermatitis. J Cutan Med Surg. 2021;25:315\u201328.","journal-title":"J Cutan Med Surg"},{"key":"792_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54\u201362.","journal-title":"Allergy"},{"issue":"7","key":"792_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.12.018.","journal-title":"J Invest Dermatol"},{"key":"792_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.14457","volume":"30","author":"A Okragly","year":"2021","unstructured":"Okragly A, Ryuzoji A, Daniels M, Patel C, Benschop R. Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab. 4th Inflammatory Skin Disease Summit, New York, November 3\u20136, 2021. Exp Dermatol. 2021;30:3\u201343.","journal-title":"Exp Dermatol"},{"issue":"4","key":"792_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411\u201320.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"792_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182\u201391.","journal-title":"JAMA Dermatol"},{"key":"792_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080\u201391.","journal-title":"N Engl J Med."},{"issue":"2","key":"792_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","volume":"117","author":"HA Sampson","year":"2006","unstructured":"Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report\u2014Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"792_CR20","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","volume":"74","author":"KL Winthrop","year":"2015","unstructured":"Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Annals Rheum Dis. 2015;74:2107\u201316.","journal-title":"Annals Rheum Dis."},{"key":"792_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad022","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad022.","journal-title":"Br J Dermatol"},{"key":"792_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.iac.2010.06.004","volume":"30","author":"BI Bielory","year":"2010","unstructured":"Bielory BI, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin North Am. 2010;30:323\u201336.","journal-title":"Immunol Allergy Clin North Am"},{"key":"792_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/cea.14127","volume":"52","author":"RE Achten","year":"2022","unstructured":"Achten RE, Bakker DS, van Luijk CM, et al. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients. Clin Exp Allergy. 2022;52:801\u20135. https:\/\/doi.org\/10.1111\/cea.14127.","journal-title":"Clin Exp Allergy"},{"key":"792_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","volume":"85","author":"NH Ravn","year":"2021","unstructured":"Ravn NH, Ahmadzay ZF, Christensen TA, Larsen HHP, Loft N, R\u00e6vdal P, Heegaard S, Kolko M, Egeberg A, Silverberg JI, Halling AS, Thyssen JP. Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;85:453\u201361.","journal-title":"J Am Acad Dermatol."},{"key":"792_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","volume":"77","author":"JP Thyssen","year":"2017","unstructured":"Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77:280\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"792_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jdv.17832","volume":"36","author":"ATM R\u00f8nnstad","year":"2022","unstructured":"R\u00f8nnstad ATM, Hansen PM, Halling AS, et al. Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey. J Eur Acad Dermatol Venereol. 2022;36:592\u2013660.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"792_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23:393\u2013408.","journal-title":"Am J Clin Dermatol"},{"key":"792_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20810","volume":"186","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Beck LA, de Bruin WM, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186:453\u201365.","journal-title":"Br J Dermatol"},{"key":"792_CR29","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/all.15326","volume":"77","author":"PM Hansen","year":"2022","unstructured":"Hansen PM, Tollenaere MAX, Hedengran A, et al. IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro. Allergy. 2022;77:2555\u20138.","journal-title":"Allergy"},{"issue":"6","key":"792_CR30","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","volume":"137","author":"SM Langan","year":"2017","unstructured":"Langan SM, Abuabara K, Henrickson SE, et al. Increased risk of cutaneous and systemic infections in atopic dermatitis\u2014a cohort study. J Invest Dermatol. 2017;137(6):1375\u20137.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"792_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","volume":"51","author":"PY Ong","year":"2016","unstructured":"Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329\u201337.","journal-title":"Clin Rev Allergy Immunol"},{"key":"792_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000331892","volume":"96","author":"A Wollenberg","year":"2012","unstructured":"Wollenberg A. Eczema herpeticum. Chem Immunol Allergy. 2012;96:89\u201395.","journal-title":"Chem Immunol Allergy"},{"key":"792_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","volume":"78","author":"P Fleming","year":"2018","unstructured":"Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78:62\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"792_CR34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187:888\u201399.","journal-title":"Br J Dermatol"},{"key":"792_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X20936059","volume":"12","author":"F Sunzini","year":"2020","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1\u201318.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"792_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100195","author":"M Kamata","year":"2023","unstructured":"Kamata M, Tada Y. Optimal use of Janus kinase inhibitors and biologics for atopic dermatitis based on the current evidence. JID Innovations. 2023. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100195.","journal-title":"JID Innovations"},{"key":"792_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/mi.2008.15","volume":"1","author":"C Blanchard","year":"2008","unstructured":"Blanchard C, Mingler MK, McBride M, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol. 2008;1:289\u201396.","journal-title":"Mucosal Immunol"},{"key":"792_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fphar.2013.00033","volume":"4","author":"MW Johansson","year":"2013","unstructured":"Johansson MW, Mosher DF. Integrin activation States and eosinophil recruitment in asthma. Front Pharmacol. 2013;4:33.","journal-title":"Front Pharmacol"},{"key":"792_CR39","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182:1120\u201335.","journal-title":"Br J Dermatol"},{"key":"792_CR40","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/0091-6749(94)90347-6","volume":"94","author":"KM Leiferman","year":"1994","unstructured":"Leiferman KM. Eosinophils in atopic dermatitis. J Allergy Clin Immunol. 1994;94:1310\u20137.","journal-title":"J Allergy Clin Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00792-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T16:32:27Z","timestamp":1687797147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00792-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00792-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"8 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These studies were funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Almirall, S.A., has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe. Eli Lilly and Company has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside of Europe.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Linda Stein Gold has been an investigator, speaker, and\/or advisory board member for: AbbVie, Amgen, AnaptysBio, Arcutis, Arena, Aslan, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Coherus, Dermira, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharmaceuticals, and UCB. Diamant Tha\u00e7i has been a consultant, investigator, speaker, and participant in scientific advisory boards for AbbVie, Almirall, Amgen, Bristol Myers Squibb, BMS, Janssen-Cilag, Galderma, Galapagos, LEO Pharma, Eli Lilly and Company, New-Bridge, Novartis, Pfizer, Regeneron, Samsung, Sanofi, Sun-Pharma, and UCB. Jacob P Thyssen has been a consultant for and\/or has received grant\/research\/honorarium support from: Regeneron, Sanofi-Genzyme, LEO Pharma, AbbVie, Eli Lilly and Company, and Pfizer. Melinda Gooderham has been a speaker, investigator, or advisory board member for: AbbVie, Amgen, Akros, AnaptysBio, Arcutis, Arena, Aslan, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Coherus, Dermira, Dermavant, Eli Lilly and Company, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, Medimmune, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Sanofi Genzyme, Sun Pharmaceuticals, Tarsus, UCB, and Ventyx. Vivian Laquer conducts research for Abbvie, Acelyrin, Acrotech, Biofrontera, Amgen, Argenx, Arcutis, Aslan, Bristol Meyers Squibb, Cara, Dermavant, Eli Lilly, Galderma, Horizon Therapeutics, Incyte, Janssen, Leo, Novartis, Padagis, Pfizer, Q32, Rapt, Sun, UCB, and Ventyx. Angela Moore has received study funds or honoraria from Abbvie, Aclaris, Acrotech, Almirall, Arcutis, Bayer, Bristol Myer Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, Pfizer, Regeneron, and UCB. Chitra R. Natalie, Fangyi Zhao, Eric Meskimen, Hany Elmaraghy, Sonia Montmayeur, and Gaia Gallo are employees and stockholders of Eli Lilly and Company. Gemma Jimenez is an employee of Almirall. M. De Bruin-Weller has been a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Amgen, Aslan, Eli Lilly and Company, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and approved by individual institutional review boards at each participating study center. Studies are registered on ClinicalTrials.gov (NCT02465606, NCT02340234, NCT03443024, NCT04146363, NCT04178967, NCT04250337, NCT04250350, NCT04392154).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and compliance with ethical standards"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the USA and European Union, and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data-sharing environment. For details on submitting a request, see the instructions provided at .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Natalie, Zhao, Meskimen, Elmaraghy, Montmayeur, and Gallo have contributed to study conception, design, analysis, and data interpretation. Zhao has contributed to study analysis and interpretation. de Bruin-Weller and Thyssen contributed to data interpretation. Jimenez contributed to data analysis and interpretation. Gooderham and Laquer contributed to the acquisition of data. Moore and Stein Gold contributed to the acquisition and interpretation of data. Tha\u00e7i contributed to the design, acquisition, and interpretation of data. All authors contributed to the drafting or critical revision of the manuscript and give final approval of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}